Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Genitourinary (GU) Tumors”

12 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 12 of 12 results

Not applicableStudy completedNCT01056562
What this trial is testing

An Alternative to A Fixed Schedule In Management Of Prostate Cancer

Who this might be right for
Prostate Cancer
University Health Network, Toronto 82
Not applicableEnded earlyNCT03134027
What this trial is testing

Reconstitution of a Human Immune System in a Patient Derived Xenograft (PDX) Model of Genitourinary (GU) Cancers

Who this might be right for
Genito Urinary CancerBladder CancerKidney Cancer+1 more
Duke University 3
Testing effectiveness (Phase 2)Ended earlyNCT02612194
What this trial is testing

LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer

Who this might be right for
Urinary Bladder NeoplasmsUreteral NeoplasmsUrethral Neoplasms
Wake Forest University Health Sciences 8
Testing effectiveness (Phase 2)Ended earlyNCT01685255
What this trial is testing

The IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy

Who this might be right for
Ovarian CancerGenitourinary (GU) Tumors
Incyte Corporation 83
Large-scale testing (Phase 3)Ended earlyNCT05171075
What this trial is testing

A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE

Who this might be right for
Venous ThromboembolismDeep Venous ThrombosisPulmonary Embolism
Anthos Therapeutics, Inc. 417
Large-scale testing (Phase 3)Ended earlyNCT01469221
What this trial is testing

Efficacy and Safety Study of Apaziquone vs. Placebo in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC)

Who this might be right for
Bladder Cancer
Spectrum Pharmaceuticals, Inc 47
Not applicableActive Not RecruitingNCT04761107
What this trial is testing

Impact of COVID-19 on GU Disease

Who this might be right for
COVID-19 InfectionGenitourinary CancerBenign Urologic Conditions
Icahn School of Medicine at Mount Sinai 15,240
Large-scale testing (Phase 3)Ended earlyNCT01410565
What this trial is testing

Efficacy and Safety of Multi-Instillations of Apaziquone in Patients With Non-Muscle Invasive Bladder Cancer

Who this might be right for
Bladder Cancer
Spectrum Pharmaceuticals, Inc 66
Not applicableNot Yet RecruitingNCT07483658
What this trial is testing

Non-inferiority Study Comparing Salvage Pelvic Radiotherapy in 25 Fractions (62.5 Gy/25) Versus 20 Fractions (52.5 Gy/20) for Recurrent Prostate Cancer After Surgery.

Who this might be right for
Reccurent/Metastatic Solid Tumor DiseaseProstate Cancer (Post Prostatectomy)Prostate Cancer+3 more
CHU de Quebec-Universite Laval 434
Not applicableLooking for participantsNCT06795087
What this trial is testing

Discharge Medication Use Post-Operatively in GU Cancer Patients

Who this might be right for
Genitourinary Cancer
Wake Forest University Health Sciences 684
Not applicableEnded earlyNCT02164942
What this trial is testing

LCI-GU-BLA-SPEC-001: Aurora Kinase Expression in Muscle-Invasive Bladder Cancer

Who this might be right for
Bladder Cancer
Wake Forest University Health Sciences 6
Not applicableUnknownNCT04870567
What this trial is testing

HDR Brachytherapy vs SABR in Early-intermediate Prostate Cancer

Who this might be right for
Biochemical Relapse Free SurvivalComplications Rates (Erectile Dysfunction, GI, GU Complications)
N.N. Petrov National Medical Research Center of Oncology 350